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Summary: By adsorption to activated charcoal, various pteridine derivatives in human urine are oxidized to
xanthopterin. Following this oxidation, xanthopterin in urine from healthy subjects and from patients with
liver diseases was assayed by high performance liquid chromatography. The mean values for xanthopterin in
healthy subjects were 532 ±116 μηιοΐ/mol creatinine (mean + SD) in males and 585 ±153 μπιοΐ/mol
creatinine in females; the difference was statistically significant (p < 0.01). Xanthopterin concentrations in
patients with liver disease were significantly higher than those in normal subjects. When compared with
urinary neopterin, which is a marker of activated cell immunity, xanthopterin was significantly increased even
in fatty liver disease. These findings suggest that increased concentrations of urinary xanthopterin in liver
diseases reflect not only the status of activated cell-mediated immunity, but also injury to liver cells.
Introduction
Many pteridine derivatives have been found in human
urine (1). Among these pteridines, neopterin has been
used as a biochemical marker of the activated state
of cell-mediated immunity, and it has been used to
monitor and screen for some clinical disorders (2 — 6).
Some current studies show that urinary neopterin
concentrations in patients with acute or chronic viral
hepatitis are higher than in normal controls (7, 8).
Urinary neopterin has also been utilized to distinguish
between chronic non-A,non-B hepatitis and liver stea-
tosis (9).
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On the other hand, little information is available on
urinary xanthopterin. An early report describes the
occurrence of the compound in human urine (1).
Urinary xanthopterin and neopterin concentrations
are found to be higher in some cancer patients (10,
11). Plesner & Kalckar (12) showed that many pteri-~
dine derivatives in urine can be oxidized, adsorbed
and eluted from activated charcoal to yield stable
xanthopterin. Because pteridine metabolism takes
place mainly in liver (13), the excretion of other pter-
idine derivatives, besides neopterin, may possibly be
an indicator of liver disease. In our preliminary study,
applying Plesner & Kalckar's extraction method, we
assayed urinary xanthopterin in patients with chronic
non-A, non-B hepatitis and in patients with fatty liver
disease (14). In the present paper we assayed urinary
xanthopterin in different types of liver disease. Uri-
nary neopterin was also determined for comparison.
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Patients and Methods
Heal thy ind iv idua l s
As controls, urine samples were collected from 178 apparently
healthy individuals (age 21 to 64 years, mean age 42), 64 were
males (age 24 to 63, mean age 44) and 114 females (age 21 to
64, mean age 40). The samples were collected during routine
medical examinations for health care workers at the Tokyo
National Sanatorium Hospital.
Patients with liver disease
Urine samples were collected from in- and out-patients in the
liver unit, Tokyo National Sanatorium Hospital. The patients
were divided into 5 groups as follows;
1) acute viral hepatitis 8 cases,
2) chronic viral hepatitis 53 cases,
3) liver cirrhosis 21 cases,
4) alcohol-induced liver disease 18 cases and
5) non-alcoholic fatty liver 13 cases.
The results of routine biochemical liver tests in each group are
shown in table 1.
Among the acute viral hepatitis cases (4 males and 4 females,
mean age 37 years), 5 were type A (anti-IgM HAV antibody
positive), 1 was type B (HBs antigen and anti-IgM HBc anti-
body positive) and 2 were type C (both above HAV and HBV
markers negative and anti-clOO-3 positive). Of the chronic viral
hepatitis cases (27 males and 26 females, mean age 57 years),
10 were type B, 33 were type C and the other 10 were type
non-A,non-B,non-C. Among the chronic viral hepatitis cases,
histological features on liver biopsy showed chronic persistent
hepatitis in 20 and chronic active hepatitis in 33. Of the liver
cirrhosis cases (16 males and 5 females, mean age 60 years), 12
were type B, 2 were type C and 7 were type non-A,non-B,non-
C. All the cases were non-alcoholic with biopsy results showing
postnecrotic cirrhosis. The alcohol-induced liver disease cases
(all 18 were males, mean age 52 years) had a long history of
alcohol abuse, with histological features showing either fatty
liver or alcoholic fibrosis with or without fat deposits. The non-
alcoholic fatty liver cases (12 males and 1 female, mean age 43
years) were considered to be due to obesity and/or metabolic
abnormalities such as hyperlipaemia or non-insulin-dependent
diabetes.
Renal failure was not present in any of the study subjects,
according to urinary and serologic tests. In addition no drugs
such as azathiopurine, corticosteroids or interferon were given
in the 6 months prior to this study.
Urine and blood sample analysjs
After the measurement of creatinine concentrations by the
alkaline picrate method, urine samples were immediately stored
at -30°C in the dark until used for the measurement of
xanthopterin and neopterin.
Blood samples were taken from all test subjects at the Tokyo
National Sanatorium Hospital at the time of urine collection.
Serum tests were performed for the following enzymes; alanine
aminotransferase, aspartate aminotransferase, γ-glutamyl
transferase. As a screening test, the zinc turbidity test was also
performed.
All analyses were conducted using a 736-40E multi-channel
autochemicai analyser (Hitachi Co., Ltd., Tokyo, Japan).
Urinary xanthopterin assay
Urinary xanthopterin was measured applying the isolation
method of Plesner & Kalckar (12) and using high performance
liquid chromatography (HPLC) for quantitation as follows: To
6 mg of activated charcoal (Norit A or Norit SX-3) 10 μΐ of
1 mol/1 acetic acid and 1 ml of urine were added successively,
mixed, and allowed to stand at room temperature for 10 min-
utes. The mixture was centrifuged at 6700 g for 5 minutes. The
resulting precipitate was washed once with distilled water, then
resuspended in 500 μΐ of 0.05 mol/1 NaOH containing 20 ml/1
pyridine. This mixture was centrifuged at 6700 g for 5 minutes
and after a 10 fold dilution of the supernate with distilled water,
50 μ! of the solution was injected into the HPLC system.
For xanthopterin determinations, the Twincle HPLC system
(Japan Spectroscopic Co., Ltd., Tokyo, Japan) was used. For
fluorescence detection, a Jasco FP-110 spectre-photometer (Ja-
pan Spectroscopic Co., Ltd., Tokyo, Japan) was used with
excitation at 390 nm and emission measurement at 460 nm. A
cut-off filter was used to eliminate detection of emission wave
lengths shorter than 460 nm. Peaks were recorded on a D-2000
chromato integrator (Hitachi Co., Ltd., Tokyo, Japan). The
HPLC column was packed with Asahipac GS 320H (Asahi
Chemical Industry Co., Ltd., Kawasaki, Japan). The elution
fluid was methanol (volume fraction 0.10) containing 10 mmol/1
potassium phosphate buffer pH 7.0 at a flow rate of 1 ml per
minute. The main peak, which showed a retention time of 10.5
minutes, was identified as xanthopterin by comparison with
authentic xanthopterin using the HPLC system described
above.
The values were expressed as μιηοΐ xanthopterin per mol cre-
atinine.
Tab. 1. Biochemical liver tests in each group of liver diseases
Cases
Reference range
Acute hepatitis
Chronic hepatitis
active
persistent
Liver cirrhosis
Alcohol-induced
liver disease
Non-alcoholic
fatty liver
(n)
(8)
(33)
(20)
(21)
(18)
(13)
Alanine
aminotransferase
(34-4 IU/1)
mean (range)
1338 (254-3468)
143 (49- 288)
48 (19- 95)
66 (10- 183)
59 (13- 185)
47 (20- 75)
Aspartate
aminotransferase
(31-9 IU/1)
mean (range)
776 (59-2428)
117 (37- 279)
41 (22- 61)
82 (14- 224)
81 (24- 212)
39 (19- 97)
γ-Glutamyl-
transferase
(33-4 mU/1)
mean (range)
130 (54-193)
92 (19-425)
39 (12-126)
67 (17-253)
198 (24-726)
• ?
74 (13-264)
Zinc
turbidity test
(13-1 Kunkel U)
mean (range)
11 (6-22)
17 (5-28)
15 (4-24)
17 (7-31)
10 (2-31)
7 (3-13)
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Urinary neopterin assay
Urinary neopterin was directly assayed without oxidation (15)
using a RIA kit "IMMUtest Neopterin" (Henning Berlin
GmbH, Berlin, Germany). Radioactivity was counted by a
programmed gamma-counter "ANSR" (Dinabot Co., Ltd., To-
kyo, Japan).
The values were expressed as μπιοί neopterin per mol creatinine.
Statistical analysis
The differences of xanthopterin values in healthy subject be-
tween different age groups were assessed by the Kruskal-Wallis
test. Using urinary xanthopterin and neopterin assay values as
data, median values for these pteridines were determined under
various conditions and evaluated by the Mann-Whitney U-test.
Comparisons of abnormal levels of xanthopterin and neopterin
were assessed by the %2-test for the different groups of patients
separately.
Tab. 2. Urinary
healthy
Age
(years)
Males
24-29
30-39
40-49
50-63
Total
Females
21-29
30-39
40-49
50-64
Total
excretion of
individuals
Number
of cases
8
18
15
23
64
24
31
27
32
114
xanthopterin and
Xanthopterin
(μηιοΐ/mol
creatinine)
mean ± SD
527 + 131
517 + 90
556 + 82
529 + 148
532 + 116
555 ± 92
592 ± 143
575 + 176
608 + 178
585 + 153
neopterin in
Neopterin
(μπιο1//ιηο1
creatinine)
mean ± SD
98 ± 55
82 + 27
90 + 42
95 + 39
91 ± 39
105 ± 26
117 + 26
125 + 39
130 + 44
120 + 38
Results
Urinary xanthopterin in healthy individuals
In 178 healthy subjects, the mean values of xantho-
pterin were 566 ±143 μπιοΐ/mol creatinine (mean
± SD). In 64 males the values were 532 ±116 μπιοί/
mol creatinine and in 114 females 585 ±153 μηιοί/
mol creatinine. Although a statistical difference in
urinary xanthopterin concentrations for males and
females was found in this present study (p < 0.01),
there were no statistically significant age group dif-
ferences (p > 0.05), as shown in table 2.
Urinary xanthopterin
in liver disease patients
As shown in table 3, urinary xanthopterin concentra-
tions in patients with liver disease including non-
alcoholic fatty liver were significantly higher than
those in healthy subjects. The highest concentrations
of xanthopterin were found in the acute hepatitis
patients, and xanthopterin concentrations were also
high in chronic active hepatitis. Urinary xanthopterin
concentrations in the active stages of chronic hepatitis
were statistically higher than in the persistent stages
(chronic active hepatitis vs. chronic persistent hepa-
titis: ρ < 0.01).
Comparison with urinary neopterin
Urinary neopterin concentrations for the same sub-
jects are also shown in table 3. Neopterin was signif-
icantly elevated in cases of acute hepatitis, chronic
hepatitis, liver cirrhosis and alcohol-induced liver dis-
ease, when compared with normal subjects. In non-
alcoholic fatty liver cases, however, there was no
significant elevation of neopterin.
Urinary concentrations of xanthopterin and neopterin
in all groups of liver disease are shown in figure 1.
Tab. 3. Urinary excretion of xanthopterin and neopterin
Group (n) Xanthopterin P(μιηοΐ/mol creatinine)
Control
Acute hepatitis
Chronic hepatitis
active
persistent
Liver cirrhosis
Alcohol-induced
liver disease
Non-alcoholic
fatty liver
178
8
33
20
21
18
13
Mean + SD
566 + 143
1305 + 579
978 ± 174
807 ± 261
934 ± 251
868 ± 248
689 ± 183
Range
250 - 902
813 - 2201
564 - 1377
536 - 1462
505- 1325
418 - 1347
435 - 993
Neopterin
(μιηοΐ/ηιοί creatinine) P
Mean + SD Range
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
<0.05
109 + 40
769 ± 571
251 + 92
224 ± 94
227 ± 99
154+ 48
125 ± 42
27-
266 -
91 -
91 -
90-
71 -
74-
232
1791
463
422
452
240
207
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
NS
NS: not significant compared with controls
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Fig. 1. Urinary concentrations of xanthopterin (A) and neopterin (B) in all groups of liver disease.
Δ: males within, Δ: males outside the range χ + 2 SD of healthy male controls,
o: females within, o: females outside the range χ Η- 2 SD of healthy female controls.
Tab. 4. Abnormal rates of xanthopterin and neopterin excre-
tion in all groups of liver disease. The relative and
absolute frequency of patients having a measured value
greater than the mean + 2 SD of normal controls are
shown
Disease
Acute hepatitis
Chronic hepatitis
active
persistent
Liver cirrhosis
Alcohol-induced
liver disease
Non-alcoholic
fatty liver
Xanthopterin
%
88
82
25
67
67
31
n
01 8)
(27/33)
(5/20)
(14/21)
(12/18)
(4/13)
Neopterin
% n
100 (8/ 8)
79 (26/33)
70 (14/20)
62 (13/21)
39 (7/18)
23 (3/13)
When the normal upper limit of each pteridine was
set at the mean + 2 SD in healthy controls, then
abnormal rates were highest in acute hepatitis and
chronic active hepatitis as seen in table 4. Mean
+ 2 SD for xanthopterin was 764 μηηοΐ/mol creati-
nine in males and 891 μηιοΐ/mol creatinine in females,
and for neopterin it was 169 μιηοΐ/mol creatinine in
males and 196 μηιοΐ/mol creatinine in females. There
was a significant difference in xanthopterin concen-
trations between chronic active hepatitis and chronic
persistent hepatitis (82% and 25%, p < 0.001), while
neopterin did not show this difference (79% and 70%,
p > 0.05).
Discussion
In the present paper a new method of urinary xan-
thopterin assay after treatment with activated char-
coal is presented. Using this method we assayed uri-
nary xanthopterin in healthy individuals and in pa-
tients with liver disease. In healthy subjects xantho-
pterin and neopterin concentrations when expressed
in μπιοΐ/πιοί creatinine were higher in females than in
males, but there were no significant age-differences in
this study. In our study populations, the concentra-
tions of urinary xanthopterin in all groμps with liver
disease were significantly higher when compared with
healthy subjects. Neopterin concentrations were also
raised, but in agreement with Prior et al. (9), there
was no significant elevation of neopterin in non-al-
coholic fatty liver.
Urinary or serum neopterin concentrations are raised
in infectious or malignant disorders with activated
cell-mediated immunity (4—6). Neopterin is mainly
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 3
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produced in human monocytes/macrophages, and its
release is accelerated upon stimulation by interferon-y
(3). In our study, urinary neopterin concentrations
were very high in acute hepatitis, and high in virus-
induced chronic liver diseases. In alcoholic liver dis-
eases, neopterin concentrations were only slightly
higher than in controls. This finding may support the
view that alcoholic hepatitis successively activates cell-
mediated immunity, and that the progress of liver
damage in spite of alcohol abstinence, is responsible
for the hyperimmune reactivity (16, 17).
The biochemistry of xanthopterin production and ex-
cretion is still scarcely known. Nevertheless, we as-
sayed xanthopterin together with neopterin. Surpris-
ingly, xanthopterin concentrations were significantly
high in all the liver disease groups mentioned above.
The increase in urinary xanthopterin, like that of
neopterin, in liver diseases may also be caused by
activated cell immunity, because the concentrations
of both are roughly correlated.
However, abnormally elevated concentrations of xan-
thopterin were found in 82% of patients with chronic
active hepatitis, but in only 25% of patients with
chronic persistent hepatitis (p < 0.001). These two
groups were histologically differentiated from those
with severe parenchymal destruction. With respect to
neopterin excretion, however, these two groups were
not significantly different (79% and 70%, p > 0.05).
Moreover, the rate of occurrence of abnormally ele-
vated urinary xanthopterin in fatty liver and other
chronic liver diseases appear to parallel the mean
values of serum aminotransferase activities. This cor-
relation does not exist for neopterin excretion. These
findings indicate that increased urinary xanthopterin
reflects liver-cell damage rather than the hyperim-
mune state.
When solutions (10~~5 mol/1) of dihydroxanthopterin,
xanthopterin, dihydroneopterin or tetrahydrobiop-
terin were mixed with equal volumes of urine and
assayed by the present method, the xanthopterin con-
centrations were found to be 1.8, 1.5, 1.3 and 1.4
times the basal concentration (unpublished data).
However, when neopterin, biopterin or dihydrobio-
pterin were examined by this method, no increase in
urinary xanthopterin was observed. Thus, the present
method represents an assay for dihydroxanthopterin,
dihydroneopterin and tetrahydrobiopterin in urine.
After treatment with activated charcoal, eluates ob-
tained by this method were fairly pure, and an HPLC
column could be used for hundreds of samples with-
out column washing. A further convenient feature of
this HPLC method is that it can be utilized in labo-
ratories where only a fluorometer is available (12).
Further studies will be undertaken of the biochemical
processes leading to the raised excretion of xantho-
pterin.
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